Shares of Mumbai-based Wockhardt Ltd have fallen down following company's recall of anti-hypertensive drug from the US market. Wockhardt is recalling about bottles of anti-hypertensive drug, Metoprolol, belonging to multiple lots from the American market following failure of dissolution test, US health regulator FDA said.
Shares were closed at Rs 776.45, down by 2.36% on BSE. Shares were slipped by 3% at Rs 770.65 intraday on Thursday. Metoprolol is a generic version of AstraZeneca’s branded drug Toprol. Tablet dissolution is a standardised method for measuring the rate of drug release from a dosage form.
According to a notification by the US Food and Drug Administration (USFDA), the recall is voluntary and was initiated by the company from April 1 under Class-II classification.
Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Metoprolol Succinate Extended-Release Tablets were distributed in the USA by Wockhardt USA.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.